Compare

DuPont de Nemours/$DD

1D1W1M3M6MYTD1Y5YMAX

About DuPont de Nemours

DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the healthcare, water, construction, automotive, aerospace, and printing and packaging industries. Healthcare and water will generate the majority of profits.
Ticker
$DD
Sector
Industrials
Primary listing
NYSE
Employees
15,000
Headquarters
Wilmington, United States
Website
www.dupont.com

DD Metrics

BasicAdvanced
$19B
359.57
$0.39
1.09
$1.20
1.71%

What the Analysts think about DD

Analyst ratings (Buy, Hold, Sell) for DuPont de Nemours stock.
Analyst projections of the future price of DuPont de Nemours stock.

Bulls say / Bears say

DuPont beat its second-quarter guidance and raised its 2026 outlook, now expecting slightly more than 4% organic sales growth and adjusted EPS of $7.17–$7.32. That gives investors evidence that earnings momentum is holding up after the portfolio changes. (PR Newswire)
Healthcare sales grew at a mid-single-digit rate, led by personal protection and biopharma, while aerospace and industrial water also showed strength. These end markets could help sustain growth in DuPont’s more focused portfolio. (PR Newswire)
DuPont generated $326 million of transaction-adjusted free cash flow in the quarter, with 127% conversion, and plans a $250 million share repurchase. Strong cash generation gives it scope to return capital while retaining capacity for targeted deals. (PR Newswire)
A new $455 million settlement with North Carolina parties will be paid over 15 years and shared with Chemours and Corteva. It resolves specific claims but underscores that legacy PFAS liabilities remain an overhang. (PR Newswire)
Water Technologies grew only at a low-single-digit rate in the second quarter, with Middle East weakness partly offsetting industrial-water and semiconductor demand. Earlier logistics disruptions had already weighed on water sales, leaving this business exposed to regional project delays. (PR Newswire, DuPont)
Healthcare & Water Technologies’ EBITDA margin fell 30 basis points to 30.1% despite sales growth, as mix and growth investments weighed on results. If that pressure persists, growth in a key high-margin segment may translate less effectively into profit. (PR Newswire, MarketBeat)
Data summarised monthly by Lightyear AI. Last updated on 11 Oct 2026.

DD Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

DD Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

DD News

AllArticlesVideos

5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps

MarketBeat5 days ago

3M, DuPont must face Connecticut firefighters' lawsuit over 'forever chemicals'

Reuters1 month ago

Baron & Budd Secures $380 Million Settlement With DuPont, Chemours, and Corteva Over North Carolina PFAS Contamination

Business Wire2 months ago

Funds containing DD

AllUSDEURGBP
Funds
Fund name
Fund size
$DD weighting
iShares S&P 500 Industrials Sector€2B7C
$787M0.35%
iShares S&P 500 Industrials Sector£IISU
$787M0.35%
Xtrackers S&P 500 Equal Weight£XDWE
$16B0.21%
Xtrackers S&P 500 Equal Weight$XDEW
$16B0.21%
iShares S&P 500 Equal Weight£EWSP
$5.1B0.21%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.